US 12,421,231 B2
Azaindole derivatives and their use as ERK kinase inhibitors
Cédric Bories, Jacou (FR); Loïc Mathieu, Lyons (FR); Jean-François Guichou, Torreilles (FR); Muriel Gelin, Clapiers (FR); and Aurélien Biechy, Boulogne-Billancourt (FR)
Assigned to AGV Discovery, Montpellier (FR); Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and Universite De Montpellier, Montpellier (FR)
Filed by AGV Discovery, Montpellier (FR); Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and Universite De Montpellier, Montpellier (FR)
Filed on Oct. 6, 2023, as Appl. No. 18/377,633.
Application 18/377,633 is a continuation in part of application No. 18/096,996, filed on Jan. 13, 2023, granted, now 11,827,637.
Claims priority of application No. 22305031 (EP), filed on Jan. 14, 2022.
Prior Publication US 2024/0308997 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5377 (2006.01); C07D 213/643 (2006.01); C07D 471/04 (2006.01); C07F 5/02 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 213/643 (2013.01); C07F 5/027 (2013.01)] 16 Claims
 
1. A method of inhibiting ERK2 kinase activity in a cell, the method comprising the step of contacting the cell with a compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is C1-C6alkyl and R2 is optionally substituted C1-C6alkyl or optionally substituted C3-C6cycloalkyl, wherein the substituent is selected from halogen, cyano, C1-C6 alkoxy, or C3-C6 cycloalkyl group; or
R1 and R2 together with a nitrogen atom to which R1 and R2 are bound form a 3- to 6-membered heterocyclic group; and
each of R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, halogen, C1-C6 alkyl substituted with C1-C6 alkoxy, trifluoromethyl, or cyano.